Načítá se...
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
OBJECTIVE: To investigate the effects of monoclonal antibodies against Aβ on cognition, function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging abnormalities (ARIA) and other adverse events, in Alzheimer’s disease (AD). METHODS: Pubmed, Web of Science, ClinicalTrials....
Uloženo v:
| Vydáno v: | Ageing Res Rev |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8161699/ https://ncbi.nlm.nih.gov/pubmed/33831607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.arr.2021.101339 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|